CO2021013251A2 - Derivados de insulina sensibles a la glucosa - Google Patents

Derivados de insulina sensibles a la glucosa

Info

Publication number
CO2021013251A2
CO2021013251A2 CONC2021/0013251A CO2021013251A CO2021013251A2 CO 2021013251 A2 CO2021013251 A2 CO 2021013251A2 CO 2021013251 A CO2021013251 A CO 2021013251A CO 2021013251 A2 CO2021013251 A2 CO 2021013251A2
Authority
CO
Colombia
Prior art keywords
insulin derivatives
glucose
sensitive insulin
diabetes
prevention
Prior art date
Application number
CONC2021/0013251A
Other languages
English (en)
Inventor
Thomas Hoeg-Jensen
Carsten Behrens
Emiliano Cló
Martin Werner Borchsenius Münzel
Per Sauerberg
Thomas Kruse
Jane Spetzler
Ulrich Sensfuss
Claudia Ulrich Hjørringgaard
Henning Thøgersen
Vojtěch Balšánek
Zuzana Drobňáková
Ladislav Drož
Vladislav Kotek
Milan Štengl
Miroslav Havránek
Ivan Šnajdr
Hana Váñová
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of CO2021013251A2 publication Critical patent/CO2021013251A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

RESUMEN La presente invención se refiere a nuevos derivados de insulina y su uso en el tratamiento o la prevención de afecciones médicas relacionadas con la diabetes. Los derivados de insulina son sensibles a la glucosa y presentan unión a la albúmina sensible a la glucosa. La invención también se refiere a nuevos productos intermedios. Por último, la invención proporciona una composición farmacéutica que comprende los derivados de insulina de la invención y el uso de dicha composición en el tratamiento o la prevención de afecciones médicas relacionadas con la diabetes.
CONC2021/0013251A 2019-03-29 2021-10-01 Derivados de insulina sensibles a la glucosa CO2021013251A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19166131 2019-03-29
EP19174671 2019-05-15
PCT/EP2020/058641 WO2020201041A2 (en) 2019-03-29 2020-03-27 Glucose sensitive insulin derivatives

Publications (1)

Publication Number Publication Date
CO2021013251A2 true CO2021013251A2 (es) 2022-01-17

Family

ID=70189906

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0013251A CO2021013251A2 (es) 2019-03-29 2021-10-01 Derivados de insulina sensibles a la glucosa

Country Status (16)

Country Link
US (1) US20220184184A1 (es)
EP (1) EP3946363A2 (es)
JP (2) JP2022527732A (es)
KR (1) KR102507156B1 (es)
CN (1) CN113646329A (es)
AU (1) AU2020255195A1 (es)
BR (1) BR112021016782A2 (es)
CA (1) CA3131832A1 (es)
CL (1) CL2021002397A1 (es)
CO (1) CO2021013251A2 (es)
IL (1) IL285664A (es)
MX (1) MX2021010988A (es)
PE (1) PE20220380A1 (es)
SG (1) SG11202108958PA (es)
TW (2) TW202112397A (es)
WO (1) WO2020201041A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4003426A4 (en) * 2019-07-31 2023-07-05 Thermalin Inc. INSULIN ANALOGUES WITH GLUCOSE-REGULATED CONFORMATION SWITCH
PE20230457A1 (es) * 2020-03-31 2023-03-10 Protomer Tech Inc Conjugados para reactividad selectiva a dioles vecinales
EP4247429A1 (en) * 2020-11-19 2023-09-27 Protomer Technologies Inc. Aromatic boron-containing compounds and insulin analogs

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU628674B2 (en) * 1989-10-19 1992-09-17 Nippon Oil And Fats Company, Limited Polymer complexes of a sugar response type
JP2005526009A (ja) * 2001-12-02 2005-09-02 ノボ　ノルディスク　アクティーゼルスカブ 新規グルコース依存性インスリン
EP2254905B1 (en) 2008-03-14 2016-12-14 Novo Nordisk A/S Protease-stabilized insulin analogues
EP2448962B1 (en) 2009-06-30 2016-10-19 Novo Nordisk A/S Insulin derivatives
WO2014093696A2 (en) 2012-12-12 2014-06-19 Massachusetts Institute Of Technology Insulin derivatives for diabetes treatment
EP3291828A4 (en) * 2015-05-06 2018-10-03 Alborz Mahdavi Glucose responsive insulins
JP2018531900A (ja) 2015-08-25 2018-11-01 ノヴォ ノルディスク アー／エス 新規インスリン誘導体及びその医学的使用
ES2956032T3 (es) * 2017-11-09 2023-12-12 Novo Nordisk As Derivados de unión a albúmina sensibles a la glucosa
KR20210005630A (ko) * 2018-04-16 2021-01-14 유니버시티 오브 유타 리서치 파운데이션 글루코스-반응성 인슐린

Also Published As

Publication number Publication date
KR102507156B1 (ko) 2023-03-09
US20220184184A1 (en) 2022-06-16
SG11202108958PA (en) 2021-09-29
BR112021016782A2 (pt) 2021-11-30
KR20210148143A (ko) 2021-12-07
JP2022527732A (ja) 2022-06-06
WO2020201041A3 (en) 2020-11-19
TW202112397A (zh) 2021-04-01
WO2020201041A2 (en) 2020-10-08
EP3946363A2 (en) 2022-02-09
MX2021010988A (es) 2021-10-01
TWI717245B (zh) 2021-01-21
IL285664A (en) 2021-10-31
CA3131832A1 (en) 2020-10-08
TW202102253A (zh) 2021-01-16
CL2021002397A1 (es) 2022-04-22
AU2020255195A1 (en) 2021-10-14
CN113646329A (zh) 2021-11-12
JP2020164525A (ja) 2020-10-08
JP6795718B2 (ja) 2020-12-02
PE20220380A1 (es) 2022-03-18

Similar Documents

Publication Publication Date Title
CO2021013251A2 (es) Derivados de insulina sensibles a la glucosa
CY1119582T1 (el) Υδατικα παρασκευασματα ινσουλινης, που περιεχουν μεθειονινη
UY29020A1 (es) Saliciltiazoles sustituidos con difenilamina o derivados de difenilamina, procedimientos para su preparacinn y su uso.-
BR112018003845A2 (pt) auxiliares cirúrgicos com medicamentos afetados por materiais ativadores
BR112015019430A2 (pt) composição farmacêutica formadora de película para curar ferimento e método para a sua preparação
AR116605A1 (es) Compuestos bifuncionales que comprenden péptidos de insulina y péptidos de egf(a)
BR122021002201A8 (pt) Composto, composição, uso de um composto, e, método de tratamento de um distúrbio, condição ou doença
CL2009000757A1 (es) Compuestos derivados de 6,8,2´-tris-(isobut-2-en-1-il)-diosmetina; procedimientos para su elaboracion; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades venosas cronicas, sindrome post-trombotico, complicaciones vasculares ligadas a la diabetes, entre otras.
CY1116064T1 (el) Συστασεις αναστολεα ddp iv
CY1119850T1 (el) Χρηση της μετφορμινης σε συνδυασμο με ενεργοποιητη γλυκοκινασης και συνθεσεων που περιλαμβανουν μετφορμινη και ενεργοποιητη γλυκοκινασης
SV2011003786A (es) Compuestos quimicos 251
DOP2009000165A (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos
BR112013024973A2 (pt) prevenção de hipoglicemia em pacientes com diabetes mellitus do tipo 2
BR112018003817A2 (pt) materiais auxiliares cirúrgicos com medicamentos afetados por ativadores
UY28726A1 (es) N-ciclohexilimidazolinonas sustituidas.procedimientos para su preparación y su uso como medicamentos.
CL2020000491A1 (es) Métodos para aumentar y/o estabilizar la función cardiaca en pacientes con enfermedad de fabry.
CL2008002356A1 (es) Sulfoxidos de piperazina-amida; sus procesos de preparacion; las composiciones farmaceuticas que los contienen; y su uso en el tratamiento de enfermedades que se modulan con agonistas lxr alfa y/o beta.
DK1680128T3 (da) Myo-inositolhexaphosphat til topisk anvendelse
CL2023000087A1 (es) Coagonistas de los receptores glp-1 y gip adecuados para el suministro oral
CY1115223T1 (el) Αντι-μελαγχολικο φαρμακο που παρασκευαζεται με υλικα camp απο τζιτζιφα
UY29846A1 (es) N-(1,3,4)-tiadiazol-2-il-bencensulfonamidas, procesos para su preparación y su uso como productos farmacéuticos
AR102778A1 (es) Composición farmacéutica, su preparación y sus usos
BR112021020496A2 (pt) Nitazoxanida e tiazolidas para uso no tratamento de doenças associadas ao estresse oxidativo
AR121038A1 (es) Derivados de insulina sensibles a glucosa
CO2023007851A2 (es) Proteínas de unión a il-7 y su uso en tratamientos médicos